More about

Nitric Oxide

News
October 02, 2019
1 min read
Save

NCX 470 reduces IOP in phase 2 trial

Nicox’s second generation nitric oxide-donating bimatoprost analog NCX 470 met the primary endpoint of non-inferiority compared with latanoprost 0.005% in a dose-ranging study, according to a company press release.

News
September 14, 2019
3 min read
Save

Explanation of HF disparities more complicated than race

PHILADELPHIA — While HF is more prevalent in the black population than in the white population, reasons for the disparity are more complicated than simply race, Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP, FHFSA, said during a plenary session at the Heart Failure Society of America Scientific Meeting.

View more